Use of novel oral anticoagulants for patients with atrial fibrillation: Systematic review and clinical implications

Heart and Lung: Journal of Acute and Critical Care

Volumn 43, Issue 1, 2014, Pages 48-59

  Albert, Nancy M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Dabigatran; Novel oral anticoagulants; Rivaroxaban; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLARITHROMYCIN; CLOPIDOGREL; CONIVAPTAN; DABIGATRAN; DRONEDARONE; ERYTHROMYCIN; FLUCONAZOLE; HEPARIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL; WARFARIN; ZAFIRLUKAST;

BLEEDING; BLEEDING TENDENCY; CEREBROVASCULAR ACCIDENT; EVENING DOSAGE; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT;

EID: 84891134203     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2013.10.014     Document Type: Review

References (82)

1. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:e269-e367.
2. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
3. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
4. Hylek E.M., Go A.S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. NEngl J Med 2003, 349:1019-1026.
5. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
6. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 suppl):e531S-e575S.
7. Boehringer Ingelheim. Pradaxa (dabigatran etexilate mesylate) Capsules Prescribing Information. Available at: ; Accessed 02.05.13. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.serαdocBase=renetnt%26folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
8. Bristol-Myers Squibb. Eliquis® (apixaban tablets) Prescribing Information. Available at: ; Accessed 04.02.13. http://packageinserts.bms.com/pi/pi_eliquis.pdf.
9. Janssen Pharmaceuticals Inc. Xarelto® (rivaroxaban tablets) Prescribing Information. Available at: ; Accessed 15.08.13. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf.
10. Hall MJ, Levant S, DeFrances CJ. Hospitalization for Stroke in U.S. Hospitals, 1989-2009. NCHS Data Brief, No 95. Available at: ; Accessed 11.09.12. http://www.cdc.gov/nchs/data/databriefs/db95.htm.
11. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
12. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
13. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
14. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
15. Gorin L., Fauchier L., Nonin E., Charbonnier B., Babuty D., Lip G.Y. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 2011, 140:911-917.
16. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
17. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
18. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
19. Kuijer P.M., Hutten B.A., Prins M.H., Buller H.R. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999, 159:457-460.
20. Lip G.Y., Frison L., Halperin J.L., Lane D.A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. JAm Coll Cardiol 2011, 57:173-180.
21. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105:91-99.
22. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
23. Shireman T.I., Howard P.A., Kresowik T.F., Ellerbeck E.F. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004, 35:2362-2367.
24. Roldan V., Marin F., Fernandez H., et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. Chest 2013, 143:179-184.
25. Gallego P., Roldan V., Torregrosa J.M., et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012, 5:312-318.
26. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. NEngl J Med 1992, 327:1406-1412.
27. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503.
28. Fonarow G.C., Albert N.M., Curtis A.B., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010, 122:585-596.
29. Gladstone D.J., Bui E., Fang J., et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009, 40:235-240.
30. Piccini J.P., Hernandez A.F., Zhao X., et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. JAm Coll Cardiol 2009, 54:1280-1289.
31. Bristol-Myers Squibb. Coumadin Prescribing Information. Available at: ; Accessed 12.04.12. http://packageinserts.bms.com/pi/pi_coumadin.pdf.
32. White H.D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
33. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364:806-817.
34. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
35. Boehringer Ingelheim International GmbH. Pradaxa® (INN - dabigatran etexilate) Summary of Product Characteristics. Available at: ; Accessed 28.09.11. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
36. Amouyel P., Mismetti P., Langkilde L.K., Jasso-Mosqueda G., Nelander K., Lamarque H. INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 2009, 20:63-69.
37. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition). Chest 2008, 133:160S-198S.
38. Van Spall H.G., Wallentin L., Yusuf S., et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012, 126:2309-2316.
39. Rose A.J., Hylek E.M., Ozonoff A., Ash A.S., Reisman J.I., Berlowitz D.R. Patient characteristics associated with oral anticoagulation control: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). JThromb Haemost 2010, 8:2182-2191.
40. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
41. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645.
42. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40:675-683.
43. Yu H.C., Tsai Y.F., Chen M.C., Yeh C.H. Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation. Int J Stroke 2012, 7:112-117.
44. Neidecker M., Patel A.A., Nelson W.W., Reardon G. Use of warfarin in long-term care: a systematic review. BMC Geriatr 2012, 12:14.
45. Fihn S.D., Callahan C.M., Martin D.C., McDonell M.B., Henikoff J.G., White R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996, 124:970-979.
46. Roy B., Desai R.V., Mujib M., et al. Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation. Am J Cardiol 2012, 109:370-377.
47. Donze J., Clair C., Hug B., et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012, 125:773-778.
48. Man-Son-Hing M., Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003, 163:1580-1586.
49. Palm F., Kleemann T., Dos S.M., et al. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2), CHA(2) DS(2)-VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol 2013, 20:117-123.
50. Rash A., Downes T., Portner R., Yeo W.W., Morgan N., Channer K.S. Arandomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007, 36:151-156.
51. Furie K.L., Goldstein L.B., Albers G.W., et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012, 43:3442-3453.
52. Wann L.S., Curtis A.B., January C.T., et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:104-123.
53. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
54. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
55. Miller C.S., Grandi S.M., Shimony A., Filion K.B., Eisenberg M.J. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110:453-460.
56. Lopes R.D., Al-Khatib S.M., Wallentin L., et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012, 380:1749-1758.
57. Jaffer A.K., Brotman D.J., Chukwumerije N. When patients on warfarin need surgery. Cleve Clin J Med 2003, 70:973-984.
58. Huang C., Siu M., Vu L., Wong S., Shin J. Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation. JEval Clin Pract 2013, 19:938-943.
59. Connolly S.J., Ezekowitz M.D., Yusuf S., Reilly P.A., Wallentin L. Newly identified events in the RE-LY trial. NEngl J Med 2010, 363:1875-1876.
60. Dowlatshahi D., Butcher K.S., Asdaghi N., et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012, 43:1812-1817.
61. Hart R.G., Diener H.C., Yang S., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43:1511-1517.
62. White R.H., Minton S.M., Andya M.D., Hutchinson R. Temporary reversal of anticoagulation using oral vitamin K. JThromb Thrombolysis 2000, 10:149-153.
63. Lip G.Y., Larsen T.B., Skjoth F., Rasmussen L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. JAm Coll Cardiol 2012, 60:738-746.
64. Schneeweiss S., Gagne J.J., Patrick A.R., Choudhry N.K., Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012, 5:480-486.
65. Baker W.L., Phung O.J. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012, 5:711-719.
66. Mantha S., Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012, 108:476-484.
67. Testa L., Agnifili M., Latini R.A., et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012, 105:949-957.
68. Kamel H., Johnston S.C., Easton J.D., Kim A.S. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012, 43:881-883.
69. Lee S., Anglade M.W., Pham D., Pisacane R., Kluger J., Coleman C.I. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012, 110:845-851.
70. Lee S., Anglade M.W., Meng J., Hagstrom K., Kluger J., Coleman C.I. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes 2012, 5:472-479.
71. Deitelzweig S., Amin A., Jing Y., et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. JMed Econ 2012, 15:776-785.
72. Pink J., Pirmohamed M., Hughes D.A. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther 2013, 94:269-276.
73. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (Supplementary Appendix). NEngl J Med 2011, 365:883-891.
74. Escolar G., Arellano-Rodrigo E., Reverter J.C., et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies invitro with circulating human blood. Circulation 2012, 126:520-521.
75. Clinicaltrials.gov. Phase 2 healthy volunteer study to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. Available at: ; Accessed 04.01.13. http://clinicaltrials.gov/ct2/show/record/NCT01758432αterm=PRT064445%26rank=1.
76. Schiele F., van Ryn J., Canada K., et al. Aspecific antidote for dabigatran: functional and structural characterization. Blood 2013, 121:3554-3562.
77. Bayer Healthcare AG. Xarelto® (rivaroxaban) Prescribing Information. Available at: ; Accessed 06.02.13. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf.
78. Granger C., Alexander J.H., Hanna M., et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial (abstract 4045). Eur Heart J 2012, 33(Abstract Supplement):685-686.
79. Patel M.R., Hellkamp A.S., Lokhnygina Y., et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). JAm Coll Cardiol 2013, 61:651-658.
80. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42:3594-3599.
81. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
82. McCabe P.J., Schumacher K., Barnason S.A. Living with atrial fibrillation: a qualitative study. JCardiovasc Nurs 2011, 26:336-344.